Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Shares of Wockhardt declined 2.15% to Rs 1,267 on the BSE.
The market size of Topiramate tablet in the USA was USD 111.47 million (MAT December 2024) as per IQVIA.
The acquisition will be funded through the initial public offer (IPO) proceeds raised by SPL. This is in line with the objects of the IPO stated in the red herring prospectus.
Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.
Wockhardt is a research based global pharmaceutical and Biotech Company.
Neuland Laboratories Ltd gained 2.02% today to trade at Rs 13000. The BSE Healthcare index is up 0.35% to quote at 41465.13. The index is up 2.44 % over last one month. Among the other constituents of the index, Wockhardt Ltd increased 1.79% and Narayana Hrudayalaya Ltd added 1.75% on the day. The BSE Healthcare index went up 18.45 % over last one year compared to the 5.39% surge in benchmark SENSEX.
Neuland Laboratories Ltd has added 14.87% over last one month compared to 2.44% gain in BSE Healthcare index and 2.09% rise in the SENSEX. On the BSE, 29 shares were traded in the counter so far compared with average daily volumes of 2530 shares in the past one month. The stock hit a record high of Rs 18089.55 on 04 Dec 2024. The stock hit a 52-week low of Rs 5557 on 04 Jun 2024.
With limited treatment options left, doctors at St. Jude’s Hospital, Memphis, USA, sought compassionate use approval from the US FDA to administer Zaynich. Over 41 days of treatment, the patient made a full recovery, marking the third successful US case treated with Wockhardt's novel β-lactam enhancer antibiotic.
Zaynich, a proprietary β-lactam enhancer antibiotic, has now been used under compassionate use in 51 critically ill patients globally, demonstrating its potential against multi-drug resistant Gram-negative infections. The drug recently completed Phase III global trials, paving the way for marketing approvals worldwide.
Wockhardt is a research based global pharmaceutical and biotech company.
The company reported consolidated net profit of Rs 14 crore in Q3 FY25 as against net loss of Rs 83 crore in Q3 FY24. Net sales rose 2.9% year on year to Rs 721 crore in Q3 FY25.